Citius Pharmaceuticals, Inc. (CTXR) Reports In-Line Q3 EPS

Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) reported Q3 EPS of ($0.06), in-line with the analyst estimate of ($0.06).

For earnings history and earnings-related data on Citius Pharmaceuticals, Inc. (CTXR) click here.

You May Also Be Interested In

• H&R Block (HRB) Tops Q4 EPS by 7c, Offers Guidance
• Kyverna Therapeutics, Inc. (KYTX) Tops Q2 EPS by 45c
• Aardvark Therapeutics (AARD) Tops Q2 EPS by 21c